Join
Live feed
·
PRReleasevia Quantisnow
Celcuity Inc. logo

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CELC· Celcuity Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CELC (Celcuity Inc.) and more on Quantisnow.